AdAlta and XL-protein in deal to develop long-acting version of lead fibrosis candidate AD-114

7 November 2016
2019_biotech_test_vial_discovery_big

Australian biotech AdAlta (ASX: 1AD) and privately-owned German firm XL-protein GmbH have agreed a collaboration to develop a long acting form of AD-114, a new drug candidate for fibrosis therapy.

AD-114 is AdAlta’s lead i-body drug candidate being developed for idiopathic pulmonary fibrosis (IPF) and a variety of other fibrotic and inflammatory diseases.

"We aim to progress AD-114 towards the clinic by early 2018"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology